Literature DB >> 31907194

Difference in Strain Pathogenicity of Septicemic Yersinia pestis Infection in a TLR2-/- Mouse Model.

Kyle L O'Donnell1, Peter L Knopick1, Riley Larsen1, Sanghita Sarkar1, Matthew L Nilles2, David S Bradley1.   

Abstract

Yersinia pestis is the causative agent of bubonic, pneumonic, and septicemic plague. We demonstrate that Toll-like receptor 2-deficient (TLR2-/-) mice are resistant to septicemic infection by the KIM5 strain of Y. pestis but not to infection by the CO92 Δpgm strain. This resistance is dependent on TLR2, the route of infection, and the isoform of YopJ. Elevated bacterial burdens were found in the spleens of CO92 Δpgm-infected animals by 24 h postinfection and in the livers by 4 days. The YopJ isoform present contributed directly to cytotoxicity and inflammatory cytokine production of bone marrow-derived macrophages from TLR2-/- mice. Immune cell trafficking is altered in CO92 Δpgm infections, with an increased neutrophil infiltration to the spleen 5 days postinfection. Immune cell infiltration to the liver was greater and earlier in KIM5-infected TLR2-/- mice. The functionality of the immune cells was assessed by the ability to develop reactive oxygen and nitrogen species. Our data suggest an inhibition of granulocytes in forming these species in CO92 Δpgm-infected TLR2-/- mice. These findings suggest that resistance to KIM5 in TLR2-/- mice is dependent on early immune cell trafficking and functionality.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  TLR2; Yersinia pestiszzm321990; host resistance; host response

Mesh:

Substances:

Year:  2020        PMID: 31907194      PMCID: PMC7035930          DOI: 10.1128/IAI.00792-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

Review 1.  Function of the Yersinia effector YopJ.

Authors:  Kim Orth
Journal:  Curr Opin Microbiol       Date:  2002-02       Impact factor: 7.934

2.  Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease.

Authors:  K Orth; Z Xu; M B Mudgett; Z Q Bao; L E Palmer; J B Bliska; W F Mangel; B Staskawicz; J E Dixon
Journal:  Science       Date:  2000-11-24       Impact factor: 47.728

Review 3.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

4.  Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation.

Authors:  Sohini Mukherjee; Gladys Keitany; Yan Li; Yong Wang; Haydn L Ball; Elizabeth J Goldsmith; Kim Orth
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

5.  The resistance of BALB/cJ mice to Yersinia pestis maps to the major histocompatibility complex of chromosome 17.

Authors:  Joshua K Turner; Milton M McAllister; John L Xu; Richard I Tapping
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

6.  Resistance to Yersinia pestis infection decreases with age in B10.T(6R) mice.

Authors:  Nathaniel D Lambert; Deanna M Langfitt; Matthew L Nilles; David S Bradley
Journal:  Infect Immun       Date:  2011-08-22       Impact factor: 3.441

7.  The dependence of the Yersinia pestis capsule on pathogenesis is influenced by the mouse background.

Authors:  Eric H Weening; Jason S Cathelyn; Greer Kaufman; Matthew B Lawrenz; Paul Price; William E Goldman; Virginia L Miller
Journal:  Infect Immun       Date:  2010-11-29       Impact factor: 3.441

8.  Kinetics of disease progression and host response in a rat model of bubonic plague.

Authors:  Florent Sebbane; Donald Gardner; Daniel Long; Brian B Gowen; B Joseph Hinnebusch
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

9.  Substrains of 129 mice are resistant to Yersinia pestis KIM5: implications for interleukin-10-deficient mice.

Authors:  Joshua K Turner; John L Xu; Richard I Tapping
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

10.  Model systems to study plague pathogenesis and develop new therapeutics.

Authors:  Matthew B Lawrenz
Journal:  Front Microbiol       Date:  2010-11-04       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.